Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition
This article was originally published in PharmAsia News
Executive Summary
In a move that will bolster its position in oncology, Eisai will buy MGI Pharma in an all-cash deal valued at $3.9 billion, the firms announced Dec. 10